These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34454810)

  • 1. Disease management with home telemonitoring aimed at substitution of usual care in the Netherlands: Post-hoc analyses of the e-Vita HF study.
    Brons M; Rutten FH; Zuithoff NPA; Oerlemans MIFJ; Asselbergs FW; Koudstaal S
    J Cardiol; 2022 Jan; 79(1):1-5. PubMed ID: 34454810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
    Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
    Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the European Society of Cardiology/Heart Failure Association website 'heartfailurematters.org' and an e-health adjusted care pathway in patients with stable heart failure: results of the 'e-Vita HF' randomized controlled trial.
    Wagenaar KP; Broekhuizen BDL; Jaarsma T; Kok I; Mosterd A; Willems FF; Linssen GCM; Agema WRP; Anneveldt S; Lucas CMHB; Mannaerts HFJ; Wajon EMCJ; Dickstein K; Cramer MJ; Landman MAJ; Hoes AW; Rutten FH
    Eur J Heart Fail; 2019 Feb; 21(2):238-246. PubMed ID: 30485612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
    Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted Strategy Based on Automated Text Messaging After a Recent Heart Failure Admission: The MESSAGE-HF Randomized Clinical Trial.
    Rohde LE; Rover MM; Hoffmann Filho CR; Rabelo-Silva ER; Silvestre OM; Martins SM; Passos LCS; de Figueiredo Neto JA; Danzmann LC; Silveira FS; Mesas CE; Hernandes ME; Moura LZ; Simões MV; Ritt LEF; Nishijuka FA; Bertoldi EG; Dall Orto FTC; Magedanz EH; Mourilhe-Rocha R; Fernandes-Silva MM; Ferraz AS; Schwartzmann P; de Castilho FM; Pereira Barretto AC; Dos Santos Júnior EG; Nogueira PR; Canesin M; Beck-da-Silva L; de Carvalho Silva M; Adolfi Júnior MS; Santos RHN; Ferreira A; Pereira D; López Pedraza L; Kojima FCS; Campos V; de Barros E Silva PGM; Blacher M; Cavalcanti AB; Ramires F;
    JAMA Cardiol; 2024 Feb; 9(2):105-113. PubMed ID: 38055237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.
    Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP
    J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
    Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).
    Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE
    Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.
    Januzzi JL; Rehman SU; Mohammed AA; Bhardwaj A; Barajas L; Barajas J; Kim HN; Baggish AL; Weiner RB; Chen-Tournoux A; Marshall JE; Moore SA; Carlson WD; Lewis GD; Shin J; Sullivan D; Parks K; Wang TJ; Gregory SA; Uthamalingam S; Semigran MJ
    J Am Coll Cardiol; 2011 Oct; 58(18):1881-9. PubMed ID: 22018299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
    J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
    McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
    J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL
    J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is 24/7 remote patient management in heart failure necessary? Results of the telemedical emergency service used in the TIM-HF and in the TIM-HF2 trials.
    Winkler S; Koehler K; Prescher S; Koehler M; Kirwan BA; Tajsic M; Koehler F
    ESC Heart Fail; 2021 Oct; 8(5):3613-3620. PubMed ID: 34182596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.